Eisai Europe

What Eisai Europe does

Eisai Europe Limited is the EMEA operating arm of Japanese pharmaceutical company Eisai Co., Ltd. (TSE: 4523), a top-20 global research-based pharmaceutical group. Registered in England and Wales and headquartered at the EMEA Knowledge Centre in Hatfield, UK, the company markets a portfolio of branded prescription medicines concentrated in two therapeutic areas: neurology (Alzheimer's disease and epilepsy) and oncology (thyroid, kidney, liver, endometrial and breast cancers), with a smaller gastrointestinal line. Key products include Leqembi (lecanemab), the first medicine authorised in the EU to slow progression of early Alzheimer's disease; Aricept (donepezil) for symptomatic Alzheimer's treatment; Fycompa (perampanel) and Inovelon (rufinamide) for epilepsy; and Halaven (eribulin) and Lenvima (lenvatinib) in oncology.

The company's underlying technology centres on the Deep Human Biology Learning (DHBL) drug discovery organisation, which formulates and tests drug-discovery hypotheses grounded in human biology across 15 global R&D sites including the G2D2 genetics-guided dementia discovery centre in Massachusetts. Eisai Europe's differentiated operational feature is the integrated EMEA Knowledge Centre in Hatfield, a 14.5-acre site combining drug discovery laboratories, a manufacturing plant producing 10 products in 29 formulations, and commercial operations under a single roof — supplying 82 countries and approximately 500,000 patients.

Commercially, Eisai Europe operates a traditional sales-led pharmaceutical model targeting specialist prescribers (neurologists, oncologists, epileptologists, psychiatrists) and national healthcare systems, with pricing set via reimbursement channels rather than publicly disclosed. Strategic alliances with Biogen (Alzheimer's), Merck & Co. and Bristol-Myers Squibb (oncology), and Nuvation Bio (taletrectinib) provide external development capacity and pipeline diversification. The company pursues an hhc (human health care) corporate philosophy and has committed to net-zero operations by 2045 with 100% renewable electricity at its UK site by 2030.

Name

Eisai Europe

Legal name

Eisai Europe Limited

Website

https://eisai.eu

Company type

Private

Founded year

1941

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Eisai Europe is the EMEA subsidiary of Japanese pharma group Eisai Co., Ltd., selling branded prescription medicines in neurology (Alzheimer's, epilepsy) and oncology across more than 40 EMEA markets, with integrated R&D, manufacturing, and commercial operations at its Hatfield, UK headquarters.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Gastroenterology Specialty Pharmaceuticals (HLAIACAE), Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

Keywords

• Prescription pharmaceuticals
• Neurology therapeutics
• Oncology medicines
• Alzheimer's disease treatments
• Drug discovery

Headquarters

HQ city

Hereford

HQ country

United Kingdom

HQ region

Europe

Offices23 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Eisai generates revenue through the sale of prescription pharmaceutical medicines in neurology and oncology therapeutic areas, including treatments for Alzheimer's disease, epilepsy, thyroid cancer, kidney cancer, liver cancer, endometrial cancer, and breast cancer.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Eisai Europe researches, develops, manufactures, and commercialises prescription pharmaceutical products primarily in neurology and oncology therapeutic areas. Its portfolio includes treatments for Alzheimer's disease (Leqembi/lecanemab, Aricept/donepezil), epilepsy (Fycompa/perampanel, Inovelon/rufinamide), hard-to-treat cancers such as thyroid, kidney, liver, endometrial, and breast cancer (Halaven/eribulin, Lenvima/lenvatinib), and gastrointestinal conditions (Pariet/rabeprazole). The company operates the EMEA Knowledge Centre in Hatfield, UK, combining in-house drug discovery, manufacturing supplying 82 countries, and commercial operations.

Product overview

Eisai Europe operates as a research-based pharmaceutical company offering a portfolio of branded medicines across oncology and neurology therapeutic areas, with a unified structure combining in-house drug discovery, manufacturing, and commercial operations through its EMEA Knowledge Centre. The product portfolio includes: oncology treatments (Leqembi/lecanemab for Alzheimer's, Halaven/eribulin, Lenvima/lenvatinib), neurology medicines (Fycompa/perampanel, Inovelon/rufinamide, Aricept/donepezil), gastrointestinal products (Pariet/rabeprazole), and patient support initiatives (FurtherMore programme). The company maintains 15 global R&D sites and operates manufacturing facilities in Hatfield, UK that produce 10 products with 29 formulations supplied to 82 countries.

Differentiator

Problem solved

Functional benefit

Brands

• FurtherMore: Metastatic breast cancer initiative showcasing real and personal experiences of women with advanced or metastatic breast cancer across the world.
• My BroadCast Companion

Products and services

• Leqembi (lecanemab) Monoclonal antibody treatment authorised in the EU as the first medicine to slow progression of early Alzheimer's disease. For healthcare professionals and patients with early Alzheimer's disease.
• Halaven (eribulin mesylate) Oncology medicine used for the treatment of breast cancer and liposarcoma. For oncologists and cancer patients with limited treatment options.
• Lenvima (lenvatinib) Tyrosine kinase inhibitor used in oncology for the treatment of thyroid cancer, renal cell carcinoma, and other cancers. For oncologists and patients with advanced solid tumours.
• Fycompa (perampanel) Antiepileptic medicine for the treatment of partial-onset seizures and primary generalised tonic-clonic seizures. For neurologists and patients with epilepsy.
• Inovelon (rufinamide) Antiepileptic medicine used as adjunctive treatment for seizures associated with Lennox-Gastaut syndrome. For neurologists and patients with refractory epilepsy.
• Aricept (donepezil hydrochloride) Acetylcholinesterase inhibitor for symptomatic treatment of mild, moderate, and severe Alzheimer's disease dementia. For neurologists, psychiatrists, and Alzheimer's patients.
• Aricept Evess Orally dispersible formulation of donepezil for Alzheimer's disease treatment, designed for patients who have difficulty swallowing tablets. For Alzheimer's patients and their caregivers.
• Pariet (rabeprazole) Proton pump inhibitor for the treatment of gastric acid-related conditions including ulcers and GERD. For gastroenterologists, primary care physicians, and patients with acid-related gastrointestinal conditions.
• FurtherMore Programme Patient support initiative for women with advanced or metastatic breast cancer, providing resources including conversation guides and the My BroadCast podcast series to support difficult conversations about the disease.

Quantifiable outcome

• Cancer mortality has decreased in nearly all European countries since 1995
• +2 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered major, core and minor.

• Nuvation BiomajorStrategic or Co-development Partner · 27 May 2026Partnership for taletrectinib (IBTROZI) for advanced ROS1-positive non-small cell lung cancer. Eisai announced EMA validation of Marketing Authorisation Application for taletrectinib in March 2026. Marketing partners for Japan and China.
• Bristol-Myers SquibbmajorStrategic or Co-development Partner · 1 January 2021Global strategic collaboration agreement in the oncology arena focused on joint development and commercialization of cancer treatments.
• Merck & Co.majorStrategic or Co-development Partner · 1 January 2018Strategic collaboration in oncology to accelerate cancer treatment development and commercialization efforts.
• BiogencoreStrategic or Co-development Partner · 1 January 2017Expanded collaboration agreement with Biogen to develop and commercialize investigational Alzheimer's disease treatments. This partnership has been central to the development of lecanemab (Leqembi), which received EU authorisation for early Alzheimer's disease in 2024.
• GHIT Fund (Phase 3)minorStrategic or Co-development Partner · 1 January 2017Eisai committed funding to the third phase of the Global Health Innovative Technology Fund in 2023 to continue advancing development of new health technologies.
• Lymphatic Filariasis Elimination ProgrammeminorStrategic or Co-development Partner · 1 January 2017Global partnership to address non-communicable diseases with pledge of continued support for elimination of lymphatic filariasis. Signed Kigali Declaration public private partnership in 2022 for neglected tropical diseases elimination.
• Global Health Innovative Technology Fund (GHIT Fund)majorStrategic or Co-development Partner · 1 January 2013Japan's first public-private partnership to advance development of new health technologies for the developing world. Eisai co-established this fund as a founding partner to address global health challenges including neglected tropical diseases.
• Academic InstitutionscoreStrategic or Co-development PartnerExternal Innovation team actively pursues partnerships with academic institutions for neurology-based collaborations including identification and validation of novel biological targets and pathways, translational biomarkers and next generation technologies in neurodegeneration.
• Non-profit OrganisationscoreStrategic or Co-development PartnerPartnerships with non-profit organisations to find new therapeutic approaches that meet the needs of patients and carers in neurodegenerative diseases.

Scale indicators14 records

Recent moves12 records

Expansion highlights6 records

Direct peers

• Biogen: US-based biotechnology company focused on neurology with a deep neuroscience pipeline. Co-developer of Leqembi/lecanemab with Eisai and the most directly comparable peer on Alzheimer's and broader CNS strategy.
• Eli Lilly: Global pharmaceutical company with a major Alzheimer's franchise (Kisunla/donanemab) directly competing with Eisai's Leqembi. Overlapping oncology and diabetes exposure makes it a comparable scaled pharma peer.
• UCB: Belgium-based pharmaceutical company specialised in neurology and immunology. Direct competitor in epilepsy with Fycompa/Inovelon and overlapping CNS focus in the European market.
• Lundbeck: Danish pharmaceutical company dedicated to brain diseases including Alzheimer's and epilepsy. Most comparable European-focused CNS specialty pharma peer to Eisai Europe's neurology franchise.

Broad incumbents

• Roche: One of the world's largest pharmaceutical companies with significant neurology and oncology portfolios. Competes with Eisai Europe in oncology (breast, lung) and offers diagnostic-adjacent CNS capabilities.
• Novartis: Swiss global pharmaceutical leader with major oncology and neurology franchises. Comparable to Eisai Europe's diversified branded pharma model with similar European scale and manufacturing footprint.
• AstraZeneca: UK-based global pharmaceutical company with a leading oncology pipeline including competing RCC and breast cancer assets. Direct comparability to Eisai Europe's oncology focus and UK manufacturing base.
• Merck & Co. US-headquartered pharmaceutical major and Eisai's oncology strategic partner since 2018. Overlapping oncology pipelines in RCC and breast cancer make it both collaborator and competitor.
• Bristol-Myers Squibb: US-based global pharmaceutical company with leading immuno-oncology franchise. Strategic oncology partner of Eisai since 2021 and a competitor in overlapping tumour indications.
• Pfizer: US-headquartered global pharmaceutical giant with broad oncology and neurology exposure. Comparable in scale and therapeutic breadth, though Eisai Europe is more concentrated in CNS.

Market position

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/eisai-emea

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eisai Europe